Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: GlobalData
$250.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Onconova Therapeutics Inc announces results from phase 3 ontime trial of Rigosertib in higher risk myelodysplastic syndromes


Wednesday, 19 Feb 2014 04:01pm EST 

Onconova Therapeutics Inc:Results From Phase 3 ONTIME Trial of Rigosertib in Higher Risk Myelodysplastic Syndromes.Rigosertib vs. Best Supportive Care did not meet the primary endpoint of statistically significant improvement in median overall survival.Post-hoc analysis demonstrates statistically significant improvement in median overall survival in patients who had progressed on or failed prior treatment with hypomethylating agents.Additional analysis of data will be discussed with regulatory authorities and presented at the 2014 ASCO Annual Meeting. 

Company Quote

5.0
 +0.00%
22 Jul 2014